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Ect2 was identified originally as a transforming pro-
tein and a member of the Dbl family of Rho guanine
nucleotide exchange factors (GEFs). Like all Dbl family
proteins, Ect2 contains a tandem Dbl homology (DH)
and pleckstrin homology (PH) domain structure. Previ-
ous studies demonstrated that N-terminal deletion of
sequences upstream of the DH domain created a consti-
tutively activated, transforming variant of Ect2 (desig-
nated N-Ect2 DH/PH/C), indicating that the N terminus
served as a negative regulator of DH domain function in
vivo. The role of sequences C-terminal to the DH domain
has not been established. Therefore, we assessed the
consequences of mutation of C-terminal sequences on
Ect2-transforming activity. Surprisingly, in contrast to
observations with other Dbl family proteins, we found
that mutation of the invariant tryptophan residue in the
PH domain did not impair N-Ect2 DH/PH/C transform-
ing activity. Furthermore, although the sequences C-
terminal to the PH domain lack any known functional
domains or motifs, deletion of these sequences (N-Ect2
DH/PH) resulted in a dramatic reduction in transform-
ing activity. Whereas N-Ect2 caused formation of la-
mellipodia, N-Ect2 DH/PH enhanced actin stress fiber
formation, suggesting that C-terminal sequences influ-
enced Ect2 Rho GTPase specificity. Consistent with this
possibility, we determined that N-Ect2 DH/PH acti-
vated RhoA, but not Rac1 or Cdc42, whereas N-Ect2
DH/PH/C activated all three Rho GTPases in vivo. Taken
together, these observations suggest that regions of Ect2
C-terminal to the DH domain alter the profile of Rho
GTPases activated in vivo and consequently may con-
tribute to the enhanced transforming activity of N-
Ect2 DH/PH/C.
Ect2, identified initially in an expression screen to search for
novel oncogene proteins expressed in epithelial cells, is a mem-
ber of the Dbl family of proteins (1). Dbl family proteins act as
guanine nucleotide exchange factors (GEFs)1 for specific mem-
bers of the Rho family of small GTPases (2, 3). Like Ras, Rho
family proteins function as GDP/GTP-regulated molecular
switches that cycle between inactive GDP-bound and active
GTP-bound states. Dbl family proteins stimulate GDP/GTP
exchange to promote formation of Rho-GTP, and the aberrant
expression of Dbl family proteins promotes growth transforma-
tion by causing persistent activation of Rho GTPases. Rho
GTPase activation in turn regulates a wide range of signaling
pathways that regulate cell cycle progression, gene expres-
sion, actin cytoskeletal organization, and many other cellular
processes (4–6).
Ect2 and essentially all Dbl family members possess a Dbl
homology (DH) domain followed by a C-terminal pleckstrin
homology (PH) domain (2, 3). The DH domain encodes the GEF
catalytic activity of these proteins. Some Dbl family members
show narrow substrate specificity and activate only specific
Rho GTPases, whereas others are more promiscuous and can
stimulate exchange on multiple Rho GTPases. The specificity of
Ect2 has not been fully resolved. One study demonstrated no
activation of RhoA, Rac1, or Cdc42 by Ect2 (1), whereas an-
other found that Ect2 could stimulate exchange on RhoA, Rac1,
and Cdc42 in vitro (7). In contrast, analyses of Pebble, the
Drosophila homolog of Ect2 (8), indicated that it is an activator
of Rho1, but not of Rac or Cdc42. However, analyses of Ect2-
mediated changes in actin organization in mammalian cells
suggested that Ect2 did not simply activate RhoA alone (9). The
basis for these different observations is unclear, and which Rho
GTPases are targets for Ect2 remain to be clarified.
Although PH domains are also found in a variety of non-
GEF signaling proteins (10, 11), the invariant, tandem
DH/PH domain topography of Dbl family GEFs suggests a
critical involvement of the PH domain in DH domain func-
tion. Detailed structural, biochemical, and biological analy-
ses have verified the critical role of the PH domain in DH
domain function, although the specific role and involvement
can vary significantly among different Dbl family proteins.
When evaluated, the PH domain has been found to be indis-
pensable for DH domain function (12–18). One exception is
Tiam1, where the DH domain-associated PH domain was
found to be dispensable for function, and instead, a second
PH domain was found to be essential for membrane associa-
tion and activity (19). Functions ascribed to the PH domain
include serving as a membrane-targeting sequence, and the
regulation of the intrinsic catalytic activity of the DH do-
main. Additionally, PH domains can bind phospholipids and
facilitate DH domain activation by phospholipid products of
phosphatidylinositol 3-kinase (20, 21). The role of the PH
domain in Ect2 function has not been determined.
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Dbl family proteins diverge significantly in the sequences
that flank the DH/PH domains. Despite this significant se-
quence divergence, a common feature of Dbl family proteins is
that N-terminal sequences upstream of the DH/PH domains
function as negative regulators of DH domain function. Hence,
deletion of N-terminal sequences causes the constitutive acti-
vation of Ect2 and other Dbl family proteins (e.g. Vav, Dbl,
Tiam1) (2, 3). Ect2 also contains sequences C-terminal to the
DH/PH domain, although no sequence relationship to known
functional protein domains or motifs, or to other proteins, have
been identified in these sequences. However, our previous anal-
yses suggested that these C-terminal sequences are important
for Ect2 transforming activity in vivo (9). In this study, we
evaluated the contribution of these C-terminal sequences to
Ect2 function. We found unexpectedly that the PH domain was
dispensable for Ect2 transforming activity. In contrast, se-
quences C-terminal to the DH/PH domains were critical for full
Ect2 transforming activity and altered the Rho GTPase speci-
ficity of Ect2 in vivo.
EXPERIMENTAL PROCEDURES
Molecular Constructs—To generate mammalian expression con-
structs that encode C-terminal variants of activated N-Ect2 (residues
415–882, amino acid numbers derived from GenBankTM accession no.
AAH23881), the pCTV3 HA3-ect2 (9) plasmid DNA was used as a
template for polymerase chain reaction (PCR)-mediated mutagenesis.
The cDNA fragments encoding N-Ect2 DH/PH/C and two C-terminal
truncation mutants were generated by PCR to modify the 5- and
3-ends to include BamHI restriction sites at each end. These fragments
encode the DH domain of Ect2 alone (residues 415–622, designated
N-Ect2 DH), the DH and PH domains of Ect2 (residues 415–775;
designated N-Ect2 DH/PH), and the DH/PH domains along with the
final 107 amino acids of the C terminus of Ect2 (designated N-Ect2)
(Fig. 1). The oligonucleotide 5-AAAGGATCCATGGTTCCTCCAAAG-
CAGTCA-3 was used as a forward primer for all three constructs. For
the ect2 DH construct, the oligonucleotide 5-TTTGGATCCTTACTC-
GAGATCAAAAATTTGCTTCTG-3 was used as the reverse primer. For
the ect2 DH/PH construct, the oligonucleotide 5-TTTGGATCCTTAG-
TCGACCACATACATAAGATTCTC-3 was used as the reverse primer.
For the ect2 DH/PH/C construct, the oligonucleotide 5-TTTGGATCCT-
TAGTCGACTATCAAGTGAGTTGTAGA-3 was used as the reverse
primer. The QuikChange mutagenesis kit (Stratagene) was used in
accordance with the manufacturer’s protocol to introduce a missense
mutation into the PH domain of N-Ect2, resulting in a change of the
invariant Trp present in essentially all Dbl family PH domains to Leu
(W752L). The primers used were 5-CCAAAGGAGAGCTTGCTGAA-
GATGCTGTGC-3 and its reverse complement 5-GCACAGCATCTT-
CAGCAAGCTCTCCTTTGG-3. The PCR-amplified fragments were
then digested with BamHI and ligated into the BamHI site of the
mammalian expression vector pCGN-hygro (gift from Michael
Ostrowski, Ohio State University) (22). This vector provides for the
attachment of a hemagglutinin (HA) epitope tag to the N terminus of
the Ect2 mutants. All constructs were sequence verified.
Guanine Nucleotide Exchange Analyses—To generate expression vec-
tors for expression and preparation of bacterially expressed fragments
of the Ect2 DH (residues 415–622) and DH/PH (residues 415–775)
domains, the corresponding fragments of Ect2 were subcloned into the
NcoI and XhoI sites of pET28a. The resulting protein products contain
a C-terminal His6 tag. Ect2 proteins were expressed in the Escherichia
coli strain BL21(DE3) for 5 h at 25 °C and purified on a nickel-charged
metal chelating column (Amersham Biosciences). Proteins were further
purified on an S200 size exclusion column (Amersham Biosciences)
equilibrated in a buffer containing 50 mM Tris, pH 8.0, 200 mM NaCl, 1
mM EDTA, 2 mM dithiothreitol, and 5% glycerol. Expression and puri-
fication of Vav2, Dbs, and GST-tagged Rho GTPases have been de-
scribed previously (23–25).
Guanine nucleotide exchange assays were conducted as described
previously (23–25). Briefly, fluorescence spectroscopic analysis of N-
methylanthraniloyl (mant)-GDP incorporation into GDP-preloaded
GST-Rac1, GST-Cdc42 or GST-RhoA was carried out using a
PerkinElmer LS 50B spectrometer at 25 °C. Exchange reaction assay
mixtures containing 20 mM Tris, pH 7.5, 50 mM NaCl, 10 mM MgCl2, 1
mM dithiothreitol, 50 g/l bovine serum albumin, 1% glycerol, 400 nM
mant-GDP (Molecular Probes), and 2 M GTPase was prepared and
allowed to equilibrate with continuous stirring. After equilibration, the
GEFs were added at the indicated concentrations, and the relative
mant fluorescence (ex  360 nm, em  440 nm) was monitored.
Experiments were performed in duplicate.
Cell Culture and Transformation Assays—NIH3T3 mouse fibroblasts
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% calf serum (Hyclone). Human embryonic kidney
293T cells were maintained in DMEM supplemented with 10% fetal calf
serum (Invitrogen). For focus formation assays, NIH3T3 cells were
transfected with 500 ng of the pCGN-ect2 mutant plasmid DNA or
pCGN-hygro empty vector by calcium phosphate precipitation, followed
by a glycerol shock as described previously (26). 14-days post-transfec-
tion, the dishes were stained with crystal violet, and the appearance of
foci of transformed cells was quantified by visual inspection.
To establish cell lines stably expressing mutant Ect2 protein,
NIH3T3 cells were transfected as above. 3-days post-transfection cells
were subcultured at a 1:3 split ratio into growth medium supplemented
with 400 g/ml of hygromycin B, and surviving colonies (50) were
pooled for future use. Western blot analyses with anti-HA antibody
(Covance) were done to verify protein expression in the established cell
lines.
For evaluation of protein expression, NIH3T3 cells were tran-
siently transfected as described. 48-h post-transfection, the cells were
lysed in protein sample buffer (27) and analyzed by SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) and Western blot analysis
with anti-HA antibody.
Transient Expression Reporter Gene Assays—For the transcriptional
transactivation assay, NIH3T3 cells were transfected by calcium phos-
phate co-precipitation as described above. 500 ng of the pCGN-hygro
empty vector or of pCGN encoding Ect2 sequences were co-transfected
together with 2 g of the luciferase reporter plasmid SRE-Luc (28),
where expression is controlled by a minimal promoter from the c-fos
gene that contains multiple serum response factor-responsive DNA
elements. 24 h after transfection, the growth medium was replaced with
DMEM supplemented with 0.5% fetal calf serum. After 16–20 h, the
cells were lysed and then analyzed for luciferase activity on an en-
hanced chemiluminescence substrate (BD Biosciences Pharmingen) in
a Monolight 2010 luminometer (Analytical Luminescence).
Immunofluorescence and Subcellular Localization Analyses—NIH3T3
cells were used to determine the subcellular location of Ect2 mutants as
previously described (29). Briefly, cells that had been plated onto cover-
slips were transiently transfected (LipofectAMINE-Plus, Invitrogen) with
the pCGN-hygro vectors expressing the Ect2 proteins. 5-h post-transfec-
tion, the medium was replaced with fresh DMEM containing 0.5% calf
serum. 24-h post-transfection, the coverslips were washed twice with
phosphate-buffered saline (PBS). The cells were then fixed in 3.7% for-
maldehyde in PBS for 10 min and incubated for 30 min in PBS supple-
mented with 0.1% Triton X-100 and 5 mg of bovine serum albumin per ml.
The coverslips were incubated with anti-HA antibody, followed by a flu-
orescein 5-isothiocyanate (FITC)-conjugated goat anti-mouse secondary
antibody (Jackson Immunoresearch Laboratories) to visualize HA
epitope-tagged Ect2 proteins, or with tetrarhodamine isothiocyanate
(TRITC)-conjugated phalloidin (Sigma) to visualize actin. Images were
then collected using an Axioskop 2 fluorescence microscope (Zeiss) and
Openlab digital imaging software (Improvision).
Membrane Fractionation Analyses—Subcellular crude fractionations
were performed as described previously (27). Briefly, NIH3T3 cells
stably expressing each HA epitope-tagged Ect2 mutant protein were
washed twice with PBS and resuspended in a hypotonic buffer (10 mM
Tris, pH 7.4, 1 mM MgCl2, 5 g/ml leupeptin, 5 g/ml aprotinin, 1 mM
phenylmethylsulfonyl fluoride) to swell on ice. The cell suspensions
were then subjected to Dounce homogenization and separated into
cytosolic (S100) and particulate (P100) fractions by ultracentrifugation
at 100,000  g in a Beckman TLS-55 rotor. The isolated fractions were
incubated with acetone to precipitate the proteins, which were then
resolved by SDS-PAGE. Western blot analysis with an anti-HA epitope
antibody was used to visualize Ect2 proteins.
Rho Activation Assay—This procedure is a modification of a previ-
ously described assay for Ras activation (30). Briefly, pGEX constructs
(Amersham Biosciences) encoding GST fusion proteins of the Rho bind-
ing domain (RBD) of either Rhotekin (amino acids 7–89) (provided by
Keith Burridge, University of North Carolina at Chapel Hill) (31) or
PAK (amino acids 70–132) (provided by Wang Lu and Bruce Mayer,
Harvard University) were expressed in bacteria, and the proteins were
then purified from clarified bacterial lysates by coupling to glutathione-
Sepharose 4B beads (Amersham Biosciences). The 293T human embry-
onic kidney epithelial cell line was transiently transfected with the
pCGN-ect2 constructs using LipofectAMINE Plus according to the man-
ufacturer’s protocol. Immediately post-transfection, cells were placed in
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medium supplemented with 0.1% serum and incubated for an addi-
tional 20 h. The GTP-bound RhoA protein was affinity-precipitated
from cell lysates as described previously (31). Briefly, the cells were
lysed in lysis buffer (50 mM Tris, pH 7.5, 500 mM NaCl, 10 mM MgCl2,
0.1% SDS, 0.5% sodium deoxycholate, 1.0% Triton X-100, and protease
inhibitors). Lysates were clarified by centrifugation at 16,000  g for 10
min. 30 micrograms of GST-Rhotekin-RBD or GST-PAK-RBD immobi-
lized on glutathione-Sepharose 4B beads were incubated with 1 mg of
clarified 293T cell lysates for 30 min at 4 °C. The beads were washed
three times in wash buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 10 mM
MgCl2, 1.0% Triton X-100, and protease inhibitors). Total and precipi-
tated lysate samples were subjected to SDS-PAGE and analyzed by
Western blot using anti-RhoA (Santa Cruz Biotechnology), anti-Rac1
(Upstate Biotechnology), and anti-Cdc42 (Transduction Laboratories)
antibodies directed against the appropriate GTPase.
In Vitro Rho GTPase Binding Analyses—pGEX 4T-1 constructs for
expression of GST-tagged fusion proteins of G15/17A dominant neg-
ative mutants of human Cdc42, Rac1, and RhoA were used as de-
scribed previously (32). Briefly, GST or GST-tagged versions of nu-
cleotide-free Rho proteins (G15A mutation for Rac1 and Cdc42, and
G17A mutation for RhoA) were expressed in bacteria, which were
lysed in lysis buffer (150 mM NaCl, 20 mM HEPES pH 7.5, 5 mM
MgCl2, 1.0% Triton X-100, 1 mM dithiothreitol, and protease inhibi-
tors) and subjected to sonication. Lysates were cleared by centrifu-
gation, incubated with glutathione-Sepharose 4B beads (Amersham
Biosciences), and washed three times in lysis buffer. Beads were
stored as a 50% slurry in HEPES-buffered saline (HBS) containing 5
mM MgCl2/glycerol (2:1). NIH3T3 cells were transiently transfected
with pCGN-N-ect2 constructs by using LipofectAMINE Plus as de-
scribed above. 20-h post-transfection, cells were lysed in lysis buffer,
cleared by centrifugation, and incubated with GST-Rho proteins
bound to Sepharose beads for 30 min. The beads were washed three
times with lysis buffer and the bound material was subjected to
SDS-PAGE and Western blot analyses with anti-HA antibody.
RESULTS
The C Terminus, but Not the PH Domain, Is Required for Ect2
Function in Vivo but Not in Vitro—Our previous analyses sug-
gested that sequences C terminus to the DH/PH domains of
N-terminally activated Ect2 were important for Ect2 transform-
ing activity (9). However, we found that the isolated fragment of
the DH/PH domains of Ect2 alone (Fig. 1) was sufficient for
robust GEF activity on RhoA, but not on Rac1 or Cdc42, in vitro
(Fig. 2). This GEF activity was equivalent to that seen for the
isolated DH/PH domain of Dbs, and the Dbs DH/PH fragment is
both fully active and highly transforming in vivo (33). Addition-
ally, we observed previously that Ect2 caused formation of lamel-
lipodia in vivo, indicating activation of Rac rather than of RhoA
(9). This apparent discrepancy between our observations of Ect2
in vitro GEF activity on RhoA and in vivo actin reorganization
suggesting activation of Rac prompted our interest in further
evaluating the role of the Ect2 C terminus in regulation of DH
domain GEF activity and specificity.
Since the boundaries of the original bacterially expressed
DH/PH domain fragment were not identical to those of the poorly
transforming Ect2 DH/PH domain fragment that we analyzed
previously in mammalian cells (9), we generated a mammalian
expression vector that encoded the same additional C-terminal
sequences (designated N-Ect2 DH/PH). We then compared its
transforming activity directly with that of the equivalent con-
struct that includes the remaining 107-residue C-terminal se-
quence of Ect2 (N-Ect2 DH/PH/C) (Fig. 1). To evaluate a role for
the PH domain in Ect2 function, we also generated an Ect2
variant that encodes the isolated DH domain of Ect2 (N-Ect2
DH). All variants of N-Ect2 were expressed as fusion proteins
that contain an N-terminal HA epitope tag to monitor expression
of the different Ect2 sequences.
We assessed the transforming activity of the different Ect2
variants using the NIH3T3 focus formation transformation
assay. Similar to what we described previously, the N-termi-
nally truncated N-Ect2 DH/PH/C protein that includes the
C-terminal sequences displayed potent transforming activity
(45 foci per dish), whereas N-Ect2 DH/PH and N-Ect2DH
proteins that lack these sequences showed little to no focus-
forming activity (Fig. 3, A and B). We then determined whether
the reduced transforming activity of the DH or DH/PH frag-
ments of Ect2 was due to impaired signaling activity. For these
analyses, NIH3T3 cells were transiently co-transfected with
Ect2 expression constructs together with a reporter plasmid
where expression of the luciferase gene is regulated by a min-
imal promoter that contains a serum response factor (SRF)-
responsive element. We found that N-Ect2 DH/PH/C caused a
7-fold stimulation of SRF activity, whereas the activity of N-
Ect2 DH/PH was reduced to 3-fold stimulation (Fig. 3C). These
results indicate that the reduced transforming activity was
due, in part, to reduced signaling activity. Thus, in contrast to
some Dbl family proteins (e.g. Dbs) where the isolated DH/PH
domains alone are sufficient for potent signaling and trans-
forming activity in vivo (33), the C terminus is required to
facilitate full activity of the Ect2 DH/PH domains in vivo.
We next evaluated the role of the PH domain in N-Ect2
DH/PH/C transforming activity. Mutation of the Trp residue
(Trp3 Leu) conserved in PH domains (Fig. 4A) and important
for domain structure has been shown to abolish the transform-
ing activity of several Dbl family proteins (12–18). Therefore,
we introduced a Trp to Leu substitution into the PH domain of
N-Ect2 DH/PH/C (designated W752L) and evaluated the con-
FIG. 1. Domain structure and protein expression levels of Ect2
mutants. A, the domain structure of full-length and truncation mutants
of mouse Ect2. BRCT (BRCA1 C terminus domains), DH domain, PH
domain, and NLS (nuclear localization signal) are shown. The N-termi-
nal-truncated and constitutively activated Ect2 variant (DH/PH/C) was
used to generate three C-terminal mutants that lacked sequences car-
boxyl to the PH domain (N-Ect2 DH/PH), lacked both the PH domain
and flanking C-terminal sequences (N-Ect2 DH) sequences, or contained
a missense mutation in the conserved Trp residue of the PH domain
(N-Ect2 DH/PH/C W752L). All N-Ect2 variant cDNA sequences were
fused in-frame to an N-terminal sequence encoding an HA epitope tag. B,
NIH3T3 cells were transiently transfected with pCGN-hygro expression
plasmids encoding each Ect2 variant. Cell lysates were normalized for
total protein (BCA protein assay kit, Pierce). Equivalent amounts of total
protein were resolved by SDS-PAGE, and Western blot analyses were
done using an anti-HA epitope antibody. Data shown are representative
of three independent experiments.
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sequence of this missense mutation on signaling, transforma-
tion, and subcellular location. The PH domain mutant of N-
Ect2 was not significantly altered in the level of protein
expressed when evaluated in transiently (Fig. 4B) or stably
transfected (data not shown) NIH3T3 cells. Surprisingly, N-
Ect2 DH/PH/C W752L showed comparable signaling and trans-
forming activity (Fig. 4, C and D) and showed the same sub-
cellular location (data not shown) as the nonmutated
counterpart. Thus, in contrast to other Dbl family proteins, this
PH domain mutation did not impair Ect2 function.
The C Terminus Does Not Alter Protein Stability or Degree of
Membrane Association—One possible mechanism by which the
C terminus may enhance N-Ect2 DH/PH transforming activ-
ity may involve increased protein stability, resulting in ele-
vated steady state levels of protein expression. To address this
possibility, we transiently transfected NIH3T3 cells with each
of the pCGN-ect2 constructs (Fig. 1B) and analyzed the cell
lysates by SDS-PAGE and Western blot analysis with an an-
ti-HA epitope antibody. The N-Ect2 DH/PH and DH variants
lacking the C-terminal sequences showed expression levels
that were comparable to or higher than that seen with N-Ect2
DH/PH/C. The same results were seen when protein expression
was evaluated in NIH3T3 cells stably transfected with the
different Ect2 expression vectors (data not shown). Thus, we
conclude that the reduced transforming activity associated
with loss of the C terminus is not a consequence of decreased
protein stability or expression.
FIG. 2. Ect2 stimulates incorporation of mant-GTP into RhoA
but not Rac1 or Cdc42. The ability of 100 nM of the isolated Ect2 DH/PH
domain to stimulate the incorporation of mant-GTP into 2 M GST-RhoA,
GST-Cdc42, or GST-Rac1 was measured by fluorescence spectroscopy
(ex  360 nm, em  440 nm). Arrows indicate the time point at which
GEF was added to the exchange reaction. Traces labeled RhoA, Cdc42,
and Rac1 represent the intrinsic GDP/GTP exchange in each of the as-
says. Positive controls were 100 nM Dbs DH/PH domain for RhoA and
Cdc42, and 200 nM Vav2 DH/PH domain for Rac1. The bottom panel is a
comparison of the GEF activities of the DH and DH/PH domains from
Ect2. The ability of 200 nM Ect2 DH (middle trace) or Ect2 DH/PH (top
trace) to stimulate the incorporation of mant-GTP into 2 M GST-RhoA
was measured by fluorescence spectroscopy as above. Data shown are
representative of two independent experiments.
FIG. 3. Deletion of Ect2 C-terminal sequences causes impair-
ment in transformation and signaling. NIH3T3 cells were trans-
fected by calcium phosphate precipitation to express pCGN-hygro ex-
pression vectors encoding the indicated proteins. Cells were maintained
in growth medium for 16 days. The cells were fixed and stained with
0.4% crystal violet (A), and the number of foci of transformed cells was
quantified by visual inspection using phase contrast microscopy (B).
Data shown are the mean of triplicate dishes with standard error
indicated by the bars and are representative of three independent
experiments. C, NIH3T3 cells were co-transfected with pCGN-hygro
expression vectors encoding the indicated proteins and with the SRF-
Luc reporter plasmid in which luciferase gene expression is controlled
by a minimal fos promoter containing tandem SRF-responsive DNA
elements. Transcriptional activation was determined by measuring
luciferase activity in cell lysates. Fold activation was determined by the
number of luciferase units in the presence of Ect2 relative to the num-
ber of units seen with empty vector control. Values represent the mean
of three independent measurements  S.E. Data shown are represent-
ative of three independent experiments.
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It is possible that the C terminus of Ect2 plays a role in
facilitating Ect2 membrane association, which could influence
Ect2 protein interaction with its membrane-bound RhoA sub-
strate. We therefore utilized fractionation analysis to address
this possibility. We subjected cell lysates from NIH3T3 cells
stably expressing the Ect2 variant proteins to high speed cen-
trifugation (100,000  g) to separate proteins into crude mem-
brane and cytoskeletal P100 and cytosolic S100 fractions (Fig.
5). Western blot analysis with anti-HA antibody showed that
N-Ect2 DH/PH/C and N-Ect2 DH/PH demonstrated similar
degrees of association with the membrane-containing P100
fraction (50%, Fig. 5). This result indicates that the C termi-
nus of Ect2 does not significantly influence the degree of mem-
brane association of Ect2.
The C Terminus Is Required for Ect2-mediated Changes in
NIH3T3 Cellular Morphology—In addition to biochemical frac-
tionation, we also utilized indirect immunofluorescence to de-
termine whether the C terminus modulated the subcellular
localization of N-Ect2. We visualized the different N-Ect2
proteins when transiently expressed in NIH3T3 cells by using
an anti-HA epitope antibody and a fluorescein-conjugated sec-
ondary antibody (Fig. 6). Whereas N-Ect2 DH showed a dif-
fuse, cytoplasmic staining, N-Ect2 DH/PH showed a similar,
but more punctate pattern, of cytoplasmic staining, with lim-
ited association with the plasma membrane (Fig. 6A). N-Ect2
DH/PH/C showed increased staining at the periphery and
along membrane ruffles (Fig. 6B). Thus, the C terminus of
N-Ect2 may influence subcellular location and association
with specific membrane compartments.
We observed that the morphology of cells expressing N-
Ect2 DH/PH/C, but not N-Ect2 DH or DH/PH, was altered
when compared with control, empty vector-transfected NIH3T3
cells. The N-Ect2 DH- and DH/PH-expressing cells looked
similar to control NIH3T3 cells (Fig. 6), whereas N-Ect2 DH/
PH/C-expressing cells displayed membrane ruffling and a less
fibroblast-like, rounded cell morphology, suggesting different
consequences on actin organization. Therefore, we compared
the actin cytoskeletal organization of these cells by immuno-
fluorescence analyses using rhodamine-conjugated phalloidin.
N-Ect2 DH-expressing cells and the control empty vector-
transfected cells displayed similar staining for actin stress
fibers, whereas the N-Ect2 DH/PH-expressing cells displayed
a significantly increased degree of staining and showed many
thick actin stress fibers traversing the cell (Fig. 6A). These
FIG. 5. Ect2 DH/PH and DH/PH/C show a similar degree of
membrane association. NIH3T3 cells stably or transiently express-
ing each HA epitope-tagged Ect2 mutant protein were lysed by Dounce
homogenization and then separated into cytosolic (S100) and particu-
late (P100) fractions by ultracentrifugation at 100,000  g. Proteins
were acetone-precipitated, resolved by SDS-PAGE, and visualized by
Western blot analysis using anti-HA epitope antibody. Data shown are
representative of three independent experiments.
FIG. 4. Mutation of the invariant
Trp residue of the PH domain does
not impair N-Ect2 DH/PH/C trans-
formation. A, alignment of sequences
flanking the invariant tryptophan residue
(indicated by arrow) found in the PH do-
mains of all (except Tiam1) Dbl family
proteins. Previous studies found that mu-
tation of the Trp residue to Leu (Trp 3
Leu) abolished transforming activity of
Dbs (12), Lsc (13), Lfc (14) Lbc (15), Vav
(16), Vav2 (17), and Net1 (18). B, muta-
tion of the PH domain of N-Ect2 does not
alter protein expression. pCGN-hygro ex-
pression vectors encoding the indicated
proteins were transiently transfected into
NIH3T3 cells. 24-h post-transfection,
cells were lysed, equivalent amounts of
total protein were resolved by SDS-
PAGE, and HA epitope-tagged Ect2 pro-
teins were visualized by immunoblotting
with anti-HA antibody. Blot analysis for
actin was done to verify equivalent load-
ing of total protein. C, mutation of the PH
domain does not impair N-Ect2 trans-
forming activity. pCGN-hygro expression
vectors encoding the indicated proteins
were transfected into NIH3T3 cells, and
focus formation was assessed after 14
days. D, quantification of focus forming
activity. Data shown are representative
of three independent experiments per-
formed in duplicate.
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results are consistent with the RhoA-specific activity that we
observed for N-Ect2 DH/PH in vitro, and with our observation
that N-Ect2 DH showed significantly reduced RhoA GEF
activity in vitro (Fig. 2). In contrast, we found two predominant
patterns of actin staining in N-Ect2 DH/PH/C-expressing
cells. Generally, these cells displayed fewer actin stress fibers
when compared with control NIH3T3 cells, and instead, lamel-
lipodia formation was observed in approximately half of the
cells (Fig. 6B, upper panel). Approximately 25% of the N-Ect2
DH/PH/C-expressing cells displayed the same rounded mor-
phology, but instead possessed actin stress fibers that were
aligned and concentrated along the cell periphery (Fig. 6B,
lower panel). Thus, whereas N-Ect2 DH/PH caused changes
in actin organization consistent with activation of RhoA, N-
Ect2 DH/PH/C caused changes that are more consistent with
Rac1 activation. These results suggested that the C terminus of
Ect2 may influence the ability of Ect2 to mediate different
types of actin reorganization by altering its GTPase specificity.
The C-terminal Sequence of Ect2 Plays a Role in GTPase
Specificity in Vivo—The analyses of actin organization sug-
gested different Rho GEF specificities for N-Ect2 DH/PH/C
and N-Ect2 DH/PH. To address this possibility, we deter-
mined the ability of the two Ect2 variants to activate Rho
GTPases in vivo by using pull-down analyses to measure the
formation of GTP-bound Rho GTPases. These analyses utilized
GST fusion proteins containing the isolated, GTP-dependent
binding domains of a Rac/Cdc42 effector (GST-PAK RBD) or of
a RhoA-specific effector (GST-Rhotekin RBD) (34–37). As ex-
pected, compared with control cells, cells expressing N-Ect2
DH/PH, a variant of Ect2 that lacks the C-terminal sequences,
displayed increased formation of GTP-bound RhoA, but not of
Rac1 or Cdc42 (Fig. 7). Surprisingly, we found that N-Ect2
DH/PH/C-expressing cells showed increased formation not only
of GTP-bound RhoA, but also of GTP-bound Rac1 and GTP-
bound Cdc42. These data suggest that the C-terminal se-
quences of Ect2 may influence the GTPase specificity of the DH
domain in vivo.
To determine if the C terminus alters the intrinsic GTPase
specificity of the DH domain, we undertook two approaches.
First, we generated a bacterial expression vector to express
N-Ect2 DH/PH/C as recombinant protein to determine
whether it could stimulate exchange on RhoA, Rac1, and Cdc42
in vitro. However, this expression construct did not yield pro-
tein that was useful for in vitro GEF analyses. Therefore, we
instead utilized dominant negative mutants of RhoA, Rac1, and
Cdc42 to assess alterations in GTPase recognition. We showed
recently that the ability of dominant negative mutants of Rho
GTPases to bind to a particular Dbl family protein corresponds
with the Rho GTPase specificity of its exchange activity (32). As
expected, dominant negative RhoA, but not Rac1 or Cdc42, was
able to form a stable complex with N-Ect2 DH/PH expressed
in cell lysates (Fig. 8). However, the same specificity of complex
formation was also seen with N-Ect2 DH/PH/C. Thus, it does
not appear that the C terminus significantly altered the ability
of the Ect2 DH domain to associate with Rac1 or Cdc42. There-
fore, the basis for the ability of N-Ect2 expression to cause
activation of Rac1 and Cdc42 in vivo does not appear to be due
simply to altered substrate binding. It remains possible that
the C terminus does directly influence Ect2 DH domain activity
in vivo, or alternatively, indirectly by a mechanism involved in
interaction with other proteins that then facilitate Rac and
Cdc42 activation.
FIG. 6. Ect2 DH/PH/C and DH/PH expressing cells exhibit dif-
ferent cellular morphology and actin reorganization. NIH3T3
cells were transiently transfected with pCGN-hygro expression vectors
encoding the DH or DH/PH (A), or DH/PH/C (B) fragments of Ect2, and
immunofluorescence was performed as described under “Experimental
Procedures.” Protein expression was detected with anti-HA antibody
followed by FITC-conjugated secondary antibody. Actin-containing
structures were visualized with TRITC-conjugated phalloidin. Data
shown are representative of three independent experiments.
FIG. 7. The C terminus of Ect2 promotes activation of RhoA,
Rac1, and Cdc42 in vivo. Human embryonic kidney cells (293T) cells
were transiently transfected with pCGN-hygro expression vectors en-
coding each N-Ect2 C-terminal variant protein. GTPase activation
was assessed by the ability to bind GST-Rhotekin (RhoA) or GST-PAK
(Rac1 and Cdc42) that was precoupled to glutathione-Sepharose beads.
Total and precipitated lysates were analyzed by Western blot using
antibodies against the appropriate GTPase. Data shown are represent-
ative of three independent experiments.
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DISCUSSION
In addition to the strictly conserved tandem DH/PH domain
structure found in essentially all Dbl family Rho GEFs, Dbl
family proteins typically show significant divergence in se-
quences that flank these two domains (2, 3). Like many Dbl
family members, Ect2 becomes constitutively active when N-
terminal sequences upstream of the DH/PH domains are de-
leted from the protein (1). Thus, these sequences serve a neg-
ative regulatory role for DH domain function in vivo. Little is
known regarding the PH domain and sequences C-terminal to
the DH/PH domains of Ect2. In contrast to many other Dbl
family GEFs, the Ect2 C terminus lacks any known functional
domains or motifs. Our previous studies suggested that the C
terminus was important for Ect2 transforming potential (9),
yet in the present study we found that the isolated DH/PH
domains of Ect2 alone displayed potent GEF activity in vitro.
Surprisingly, we determined that these C-terminal sequences
altered the Rho GTPase specificity of the Ect2 DH domain in
vivo. Whereas the Ect2 DH/PH domains alone activated RhoA
in vitro and in vivo, the DH/PH/C fragment activated not only
RhoA, but also Rac1 and Cdc42 in vivo. Thus, sequences beyond
the DH and PH domains may influence the GTPase specificity
of Ect2. Finally, in contrast to other Dbl family proteins, mu-
tation of the conserved Trp residue in the PH domain did not
impair Ect2 subcellular location or transforming activity.
Therefore, the presence of the C-terminal sequences may com-
pensate for the loss of Ect2 PH domain function.
The invariant DH/PH domain topography seen in the major-
ity of Dbl family GEFs suggests the critical role of the PH
domain in DH domain function (2, 3). Consistent with this
possibility, previous studies found that mutation of the con-
served PH domain Trp residue to Leu (Trp 3 Leu) abolished
the transforming activity of all Dbl family proteins evaluated,
including Dbs (12), Lsc (13), Lfc (14), Lbc (15), Vav (16), Vav2
(17), and Net1 (18). In contrast, the adjacent PH domain was
found to be dispensable for Tiam1 function, and instead, a
second PH domain N-terminal to the DH/PH domains was
found to be essential for GEF activity in vivo (19). Interest-
ingly, this Trp residue is not conserved in the DH domain-
associated PH domain of Tiam1; instead, Tiam1 contains a Phe
at this position. Thus, we were surprised to find that mutation
of the Trp residue in the Ect2 PH domain did not impair
N-Ect2 DH/PH/C transforming activity. We would not have
predicted this result based on our observation that the DH/PH
domain fragment showed greater activity than the DH domain
alone in vitro. One possible explanation may be that, while
mutation of this residue is generally considered to abolish PH
domain function, perhaps this is not the case with the Ect2 PH
domain. Alternatively, perhaps the C terminus provides a func-
tion that renders the PH domain dispensable.
Studies examining the Rho GTPase substrate specificity of
Ect2 have reached conflicting conclusions. Miki and co-workers
(7) showed that full length Ect2, immunoprecipitated from
mammalian cells, catalyzed exchange on RhoA, Rac1, and
Cdc42 in vitro. In contrast, the function of the Drosophila
homolog of Ect2, Pebble, suggests that it acts as a RhoA-
specific Rho GEF (8). Furthermore, our analyses in the present
study found that the isolated DH/PH domains of Ect2 acted as
a RhoA-specific exchange factor in vitro and in vivo. The DH
domain of Ect2 exhibits strongest sequence identity with the
DH domain of GEF720/KIAA0720 (2), a RhoA-specific GEF
(38). However, when we characterized Rho GEF activity in vivo
for the DH/PH/C fragment, we showed that this mutant caused
increased levels of RhoA-GTP, Rac1-GTP and Cdc42-GTP in
vivo. One possible explanation for the conflicting results may
be that different fragments of Ect2 protein (i.e. full-length,
DH/PH/C, or DH/PH) have been used in different studies. Our
results are consistent with those of Miki and co-workers (7),
who isolated full length Ect2 expressed in COS cells to perform
their exchange assays. Although this protein is not N-termi-
nally truncated, it does contain the full C-terminal sequence.
Taken together, these results all suggest that when the C-
terminal end is not deleted, N-Ect2 can activate RhoA, Rac1,
and Cdc42. The manner in which the Ect2 protein is expressed
(mammalian versus bacterial) may also influence the specific-
ity. Ect2 contains two putative Cdc2 phosphorylation sites, one
of which is located in the C terminus. Miki and co-workers (7)
stated that phosphorylation of Ect2 is required for the ex-
change activity, though they showed only the exchange activity
on Rac1 protein. It is possible that the GEF activity on Rac1
requires the C terminus of Ect2 to be phosphorylated, which
would occur when expressed in mammalian cells, but not when
expressed in bacteria. This may explain why Miki and col-
leagues first found that Ect2 did not display exchange activity
for Rac1 (1). Unfortunately, we have not been able to isolate a
bacterially expressed version of the Ect2 DH/PH/C to evaluate
the possibility that the C terminus can influence DH domain
specificity in vitro.
The lamellipodia-like structures that we observed with N-
Ect2 DH/PH/C also support our Rho GTPase activation results
and indicate that Ect2 is an activator of Rac1 in vivo. Our
previous study found that N-Ect2 caused an unusual cellular
morphology with lamellipodia-like structures similar to that
induced by Rac1 (9). It is also possible that Rho GTPases other
than the well studied Rac1, Cdc42, and RhoA could be targets
for Ect2. For example, TCL and RhoG can also promote lamel-
lipodia formation (39). Therefore, to fully understand the con-
sequences of Ect2 function, a complete understanding of its
Rho GTPase targets will be needed.
In summary, the studies presented here indicate that the C
terminus of Ect2 is important for its transforming activity and
signaling properties, and can influence the GTPase specificity
of the DH domain. With the possible exception of Vav, where
the cysteine-rich domain adjacent to the PH domain may in-
fluence substrate specificity (40), the Rho GTPase specificity of
Dbl family GEFs typically resides in the DH domain. How the
C terminus influences the Rho GTPase specificity of the Ect2
FIG. 8. The C terminus does not alter Ect2 interaction with
RhoA, Rac1, or Cdc42 in vitro. HA epitope-tagged versions of N-
Ect2 DH/PH/C or N-Ect2 DH/PH proteins, or of control Vav2 and Dbs
proteins, were expressed transiently in NIH3T3 cells. Dominant nega-
tive Rho GTPases were expressed in bacteria as GST fusion proteins
and precoupled to glutathione-Sepharose beads. Cell lysates were
passed over the beads, and stable complexes formed between the GEFs
and Rho proteins that remained bound following centrifugation and
washing were resolved on SDS-PAGE and detected by immunoblotting
with anti-HA antibody. Data shown are representative of three inde-
pendent experiments.
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DH domain, and whether other GTPases are also activated,
remain to be determined.
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